tbuckley/cabot-search huggingface dataset:
CSIG-25. MiR-338-3p AS A TUMOR SUPPRESSOR THROUGH Pttg MODULATION IN GH3 CELL LINES
Authors: Jin Mo Cho, Yangjong Lee, Cheol Ryong Ku, Wonjin Kim, Sun Ho Kim, eun Jig Lee
Journal: Neuro-Oncology (2016)

MicroRNAs (miRNA) are relatively small nucleotide composed of 20-30 nucleotide which noncoding RNAs that are found in the genomes of animal, plants, and protozoa. miRNAs regulate post-transcriptional expression of target genes predominantly by inhibiting or enhancing protein translation or degrading the target mRNA. Recent studies suggest that aberrant microRNA expression is common in numerous malignancies. Although miR-338-3p has been implicated in several gastrointestinal cancers, its role in pituitary adenoma is unknown. We treated miR-338-3p mimic and inhibitor on rat Growth Hormone (GH) secreting cell line (GH3) to invastigate the biological role of expression level alteration of miR-338-3p. After treatment of mimic and inhibitor, quantitative RT-PCRs(QPCRs) were performed with several targets, that are predicted to affect both hormone secreting system and tumorigenesis. Western blotting was also performed to double-check the results from QPCRs. Evaluating the effect of miR-338-3p on invasiveness, microRNA microarray was performed with 6 patients. The miRNA Microarray System with miRNA Complete Labeling and hybridization Kit (Agilent Technologies) was used according to the manufacturer′s recommended protocol. There were some research about predictive markers of pituitary adenoma behavior, but most of them were restricted to non-functioning pituitary. Although the assumption of prognosis of pituitary adenoma, there was no known about behavior marker for GH secretory adenoma. Lately, microRNA has become of general interest as a cancer biomarker. Our research on several targets, such as prolactin, growth hormone, pttg1, and, gpr101 after mimic and inhibitor of miRNA-338 imply that miRNA-338 could be involved in hormone secretion system and tumorigenesis. FACs data shows good chance of miR-338-3p’s role of cell cycle regulator. In patient sample, mir-338-3p expression level was relatively high, which means it is also related to invasiveness of pituitary adenomas. We need more experiments to form organic connection among our data, for there are no sufficient additional evidences that support them.
Studies on Myocarditis in Childhood, with Special Reference to the Possible Role of Immunological Process and the Thymus in the Chronicity of the Disease
Authors: Masahiko Okuni, Tadamasa Yamada, Shuntaro Mochizuki, Isamu Sakurai
Journal: Circulation (1975)

Twenty-one cases of idiopathic myocarditis were studied. Fulminant form 1 case, acute fatal form 2 cases, acute benign form 4 cases, recurrent form 1 case. Chronic dilated form 2 cases progressive hypertrophy form 2 cases and asymptomatic and sudden death form was 10 cases. Clinical signs and symptoms of these cases were manifold. Also laboratory findings were nonspecific. Ten cases of latent myocarditis which showed sudden death syndrome were found among 47 cases, progressive hypertrophy form 2 cases and children. Early detection of latent myocarditis is considered to be necessary for preventing sudden death syndrome in school children. The relationship between cardiomyopathy and idiopathic myocarditis was discussed. Two cases of idiopathic myocarditis simulating cardiomyopathy were presented. The pathogenesis of chronicity in idiopathic myocarditis was discussed. Bound gammaglobulin in heart muscle was detected in a case showing progressive hypertrophy of the ventricles. Autopsy results showed a previously undescribed finding that the cases having normal thymus/body weight ratio tended to have markedly increased heart weight but the cases having increased thymus/body weight ratio tended to have near normal heart weight. These results are considered to suggest the possible role of immunity in the chronicity of idiopathic myocarditis.
Cutaneous responses in Her-2+ metastatic breast cancer (MBC) on phase 1b study of ONT-380, an oral HER2-specific inhibitor in combination with capecitabine (C) and/or trastuzumab (T) in third line or later treatment
Authors: A.K. Conlin, V.F. Borges, N.M. Moxon, L.N. Walker, S.L. Moulder
Journal: Annals of Oncology (2016)
Desaminases for Ribosenucleic and Desoxyribosenucleic Acids1
Authors: Jesse P. Greenstein, Howard W. Chalkley
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Desaminases for Ribosenucleic and Desoxyribosenucleic Acids Get access Jesse P. Greenstein, Jesse P. Greenstein Search for other works by this author on: Oxford Academic PubMed Google Scholar Howard W. Chalkley Howard W. Chalkley Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 1, August 1945, Pages 61–72, https://doi.org/10.1093/jnci/6.1.61 Published: 01 August 1945
PDTB-08. Mir-449a, A POTENTIAL DIAGNOSTIC BIOMARKER FOR WNT GROUP OF MEDULLOBLASTOMA
Authors: Qing Chang, Yong-Xiao Li
Journal: Neuro-Oncology (2016)

Medulloblastoma (MB) is the most common malignant brain tumor in childhood. The five year disease-free survival rate is rather low. There is a consensus that MB can be divided into at least four clinically, transcriptionally, and genetically distinct molecular variants, being designated as wingless (WNT), sonic hedgehog (SHH), Group 3 and Group 4. It poses a great challenge to the design of therapeutic strategy for MB patients. Intensive clinical intervention, including high dose radiotherapy, is commonly used in treatment of high risk MB, most of which are considered to be Group 3 patients. But such intensive therapy should be avoided to protect neurologic function of patients in the lower risk WNT group. In present study, MB subgroup assignment in formalin-fixed paraffin embedded (FFPE) specimens from 45 Chinese patients were performed by Nanostring platform using 22 well-known signature genes. Based on comparative expression profiles of miRNA real-time PCR microarray in MB cells with and without treatment of demethylation reagent, as well as MSP assay, miR-449a was demonstrated to be significantly silenced by aberrant DNA methylation in tumor cells. Real-time PCR showed that expression level of miR-449a in WNT group was significantly different from other subgroups, although it was down-regulated in most of the MB samples. In conclusion, current study demonstrates for the first time the feasibility of using the Nanostring assay for subgrouping of medulloblastomas in Chinese patients. In addition, MiR-449a, a candidate tumor suppressor regulated by hypermethylation, is a novel potential diagnostic marker for WNT group of MBs.
Prevalence of Anti-HLA and Anti-GPIIB/IIIA Allo-Immunization in Patients with Glanzmann Thromboasthenia: Experience of a Single Center.
Authors: Cristina Santoro, Angela Rago, Angela Antenucci, Antonio Chistolini, Laura Conti, Annalisa De Vellis, Lucia Di Renzo, Luca Laurenti, Mariapaola Perrone, Robert Foa, Mariagabriella Mazzucconi
Journal: Blood (2006)
miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting<i>ADAM9</i>and<i>TGFBR2</i>
Authors: Jasmijn G.M. van Kampen, Onno van Hooij, Cornelius F. Jansen, Frank P. Smit, Paula I. van Noort, Iman Schultz, Roel Q.J. Schaapveld, Jack A. Schalken, Gerald W. Verhaegh
Journal: Cancer Research (2017)

Reversing epithelial-to-mesenchymal transition (EMT) in cancer cells has been widely considered as an approach to combat cancer progression and therapeutic resistance, but a limited number of broadly comprehensive investigations of miRNAs involved in this process have been conducted. In this study, we screened a library of 1120 miRNA for their ability to transcriptionally activate the E-cadherin gene CDH1 in a promoter reporter assay as a measure of EMT reversal. By this approach, we defined miR-520f as a novel EMT-reversing miRNA. miR-520f expression was sufficient to restore endogenous levels of E-cadherin in cancer cell lines exhibiting strong or intermediate mesenchymal phenotypes. In parallel, miR-520f inhibited invasive behavior in multiple cancer cell systems and reduced metastasis in an experimental mouse model of lung metastasis. Mechanistically, miR-520f inhibited tumor cell invasion by directly targeting ADAM9, the TGFβ receptor TGFBR2 and the EMT inducers ZEB1, ZEB2, and the snail transcriptional repressor SNAI2, each crucial factors in mediating EMT. Collectively, our results show that miR-520f exerts anti-invasive and antimetastatic effects in vitro and in vivo, warranting further study in clinical settings. Cancer Res; 77(8); 2008-17. ©2017 AACR.
Impact of second primary tumors of head and neck region after a previous tumor in that area
Authors: C. Salvador Coloma, J.T. Amerigo, Ó.M. Niño, J. Caballero Daroqui, D. Akhoundova, C. Escoin, M. Melián Sosa, E. Navarro, J. Montalar, M. Pastor
Journal: Annals of Oncology (2016)
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
Authors: Adrian R Martineau, David A Jolliffe, Richard L Hooper, Lauren Greenberg, John F Aloia, Peter Bergman, Gal Dubnov-Raz, Susanna Esposito, Davaasambuu Ganmaa, Adit A Ginde, Emma C Goodall, Cameron C Grant, Christopher J Griffiths, Wim Janssens, Ilkka Laaksi, Semira Manaseki-Holland, David Mauger, David R Murdoch, Rachel Neale, Judy R Rees, Steve Simpson, Iwona Stelmach, Geeta Trilok Kumar, Mitsuyoshi Urashima, Carlos A Camargo
Journal: BMJ (2017)

<b>Objectives</b>&nbsp;To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and to identify factors modifying this effect. <b>Design</b>&nbsp;Systematic review and meta-analysis of individual participant data (IPD) from randomised controlled trials. <b>Data sources</b>&nbsp;Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and the International Standard Randomised Controlled Trials Number registry from inception to December 2015. <b>Eligibility criteria for study selection</b>&nbsp;Randomised, double blind, placebo controlled trials of supplementation with vitamin D<sub>3</sub> or vitamin D<sub>2</sub> of any duration were eligible for inclusion if they had been approved by a research ethics committee and if data on incidence of acute respiratory tract infection were collected prospectively and prespecified as an efficacy outcome. <b>Results</b>&nbsp;25 eligible randomised controlled trials (total 11 321 participants, aged 0 to 95 years) were identified. IPD were obtained for 10 933 (96.6%) participants. Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants (adjusted odds ratio 0.88, 95% confidence interval 0.81 to 0.96; P for heterogeneity &lt;0.001). In subgroup analysis, protective effects were seen in those receiving daily or weekly vitamin D without additional bolus doses (adjusted odds ratio 0.81, 0.72 to 0.91) but not in those receiving one or more bolus doses (adjusted odds ratio 0.97, 0.86 to 1.10; P for interaction=0.05). Among those receiving daily or weekly vitamin D, protective effects were stronger in those with baseline 25-hydroxyvitamin D levels &lt;25 nmol/L (adjusted odds ratio 0.30, 0.17 to 0.53) than in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (adjusted odds ratio 0.75, 0.60 to 0.95; P for interaction=0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted odds ratio 0.98, 0.80 to 1.20, P=0.83). The body of evidence contributing to these analyses was assessed as being of high quality. <b>Conclusions</b>&nbsp;Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall. Patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit. <b>Systematic review registration</b>&nbsp;PROSPERO CRD42014013953.
O-018 Clinical application of targeted next generation sequencing for colorectal cancer patients: a multicentric Belgian experience
Authors: Q. Fontanges, M. Le Mercier, N. De Nève, O. Blanchard, M. Delos, F. Dehou Marie, C. Maris, N. Nagy, E. Rousseau, J. Vandenhove, A. Gilles, C. De Prez, L. Verset, M.-P. Van Craynest, P. Demetter, J.L. Van Laethem, I. Salmon, N. D'Haene
Journal: Annals of Oncology (2016)
Sensitive NOD-scid-IL2γnull (NOG-scid) Assay for Human Precursor B Acute Lymphoblastic Leukemias (ALL).
Authors: Sebastien Morisot, Richard Hildreth, Ian M. Kaplan, Maryalice Stetler-Stevenson, Julie A. Taylor, Yachna Ahuja, Lauren Bloom, Alan S. Wayne, Curt I. Civin
Journal: Blood (2007)
Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis
Authors: M Ratnaparkhe, M Hlevnjak, T Kolb, A Jauch, K K Maass, F Devens, A Rode, V Hovestadt, A Korshunov, A Pastorczak, W Mlynarski, S Sungalee, J Korbel, J Hoell, U Fischer, T Milde, C Kramm, M Nathrath, K Chrzanowska, E Tausch, M Takagi, T Taga, S Constantini, J Loeffen, J Meijerink, S Zielen, G Gohring, B Schlegelberger, E Maass, R Siebert, J Kunz, A E Kulozik, B Worst, D T Jones, S M Pfister, M Zapatka, P Lichter, A Ernst
Journal: Leukemia (2017)
MPTH-28. ACID CERAMIDASE IS A SUPPLEMENTARY BIOMARKER OF SURVIVAL IN GLIOMA
Authors: Mona M. Al-Gizawiy, Ninh B. Doan, Kathleen M. Schmainda, Jose A. Palomares, Wade M. Mueller, Jennifer M. Connelly, Shama P. Mirza
Journal: Neuro-Oncology (2016)
Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.
Authors: Rakesh Popat, Catherine Williams, Mark Cook, Charles Craddock, Supratik Basu, Charles Singer, Liz Odeh, Nicola Foot, Simon Hallam, Heather Oakervee, James D. Cavenagh
Journal: Blood (2007)
Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
Authors: R.S. Kristeleit, R. Shapira-Frommer, A. Oaknin, J. Balmaña, I.L. Ray-Coquard, S. Domchek, A.V. Tinker, C.M. Castro, S. Welch, A.M. Poveda, K. Bell-Mcguinn, G. Konecny, H. Giordano, L. Maloney, S. Goble, L. Rolfe, A. Oza
Journal: Annals of Oncology (2016)
Neuroscience in gambling policy and treatment: an interdisciplinary perspective
Authors: Murat Yücel, Adrian Carter, Amy R Allen, Bernard Balleine, Luke Clark, Nicki A Dowling, Sally M Gainsbury, Anna E Goudriaan, Jon Grant, Alan Hayes, David Hodgins, Ruth van Holst, Ralph Lattimore, Charles Livingstone, Valentina Lorenzetti, Dan Lubman, Carsten Murawski, Linden Parkes, Nancy Petry, Robin Room, Bruce Singh, Anna Thomas, Phil Townshend, George Youssef, Wayne Hall
Journal: The Lancet Psychiatry (2017)
Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).
Authors: Carola Boccomini, Marco Ladetto, Luigi Rigacci, Luca Arcaini, Manuela Ceccarelli, Chiara Lobetti-Bodoni, Stefano Volpetti, Lorella Orsucci, Annalisa Chiarenza, Roberto Freilone, Paolo Corradini, Silvia Bolis, Silvia Franceschetti, Paola Riccomagno, Chiara Rusconi, Alfonso Zaccaria, Caterina Stelitano, Anna Marina Liberati, Chiara Ciochetto, Luca Baldini, Monica Balzarotti, Alessandra Tucci, Umberto Vitolo
Journal: Blood (2012)
Circulating IL-6 upregulates IL-10 production in splenic CD4+ T cells and limits acute kidney injury–induced lung inflammation
Authors: Ana Andres-Hernando, Kayo Okamura, Rhea Bhargava, Carol M. Kiekhaefer, Danielle Soranno, Lara A. Kirkbride-Romeo, Hyo-wook Gil, Chris Altmann, Sarah Faubel
Journal: Kidney International (2017)
Impact of tumor epidermal growth factor receptor (EGFR) status on the outcomes of first-line FOLFOX-4 ± cetuximab in patients (pts) with RAS-wild-type (wt) metastatic colorectal cancer (mCRC) in the randomized phase 3 TAILOR trial
Authors: S. Qin, J. Xu, L. Wang, Y. Cheng, T. Liu, J. Chen, S.P. Eggleton, J. Liu, J. Li
Journal: Annals of Oncology (2016)
A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC)
Authors: F. Karzai, A. Zimmer, S. Lipkowitz, C.M. Annunziata, B. Parker, N. Houston, I. Ekwede, E.C. Kohn, J.-M. Lee
Journal: Annals of Oncology (2016)
ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM
Authors: Caroline Happold, Riccardo Soffietti, Christine Marosi, Jaap Reijneveld, Gabriele Schackert, Astrid Weyerbrock, Jennifer Clarke, François Ducray, Peter Hau, Antoine Carpentier, Jörg Felsberg, Patrick Roth, Vassilis Golfinopoulos, Martin Klein, Guido Reifenberger, Michael Weller
Journal: Neuro-Oncology (2016)

Patients with glioblastoma survive rarely beyond five years. Long-term survivors are typically young, have had gross total tumor resection, and their tumors more often exhibit two prognostically ­favorable molecular aberrations: isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Other determinants of long-term survival have remained obscure. A consortium of more than 20 clinical sites in Europe, the US and Australia registers patients with glioblastoma who survived for at least 5 years. The pathological diagnosis of glioblastoma is centrally reviewed. Data on clinical disease characteristics including imaging data are collected at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium. Alive patients will be prospectively followed clinically and by neurocognitive assessments. The goal is to better understand the contribution of (i) patient factors, (ii) tumor parameters, (iii) therapy and care and (iv) immunological parameters to prolonged survival. At the cut-off of May 31, 2016, 103 patients have been registered by 10 sites; 53 patients are deceased and 50 patients are alive; 36 patients have undergone one, 11 patients have undergone two neurocognitive assessments. Updated clinical disease characteristics with a cut-off of September 30, 2016, will be presented. We hope that this consortium, generously supported by the Brain Tumor Funders’ Collaborative, will contribute to a better understanding of the natural history of glioblastoma, a comprehensive characterization of the molecular and physiological determinants of long-term survival, and the individual patient parameters that may modulate disease course.
CBIO-12. SIX EXTRACELLULAR VESICLE RELATED GENES CAN EXPLAIN THE PRO-TUMORIGENIC BEHAVIOR OF HETEROGENEOUS HIGH GRADE GLIOMAS
Authors: Franz Ricklefs, Marco Mineo, Arun Kumar Rooj, E. Antonio Chiocca, Jakub Godlewski, Agnieszka Bronisz
Journal: Neuro-Oncology (2016)
Unmanipulated HLA-Haploidentical (2-3 antigen-mismatched) Stem Cell Transplantation Using Myeloablative or Reduced-Intensity Preconditioning Regimen,
Authors: Katsuji Kaida, Kazuhiro Ikegame, Satoshi Yoshihara, Kyoko Taniguchi, Shinichi Ishii, Ruri Kato, Takayuki Inoue, Masaya Okada, Hiroya Tamaki, Tatsuya Fujioka, Toshihiro Soma, Hiroyasu Ogawa
Journal: Blood (2011)
The pharmacokinetics of methotrexate with and without rituximab in the treatment of primary central nervous system lymphoma (PCNSL)
Authors: F.R. Rawat, A. Nolan, S.Y. Teo, M. Triggs, G. Carroll, S. Picardo, N.M. Keegan, V. Mallett, I. Ismail, B. Hennessy, W. Grogan, O. Breathnach, P. Morris
Journal: Annals of Oncology (2016)
ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC)
Authors: J. Wolf, I.-J. Oh, J. Mazieres, J. de Castro, C. Revil, A. Kotb, H. Johansdottir, A. Zeaiter, S. Novello
Journal: Annals of Oncology (2016)
Screening for<i>Chlamydia trachomatis</i>Infections in Women
Authors: Harold C Wiesenfeld
Journal: New England Journal of Medicine (2017)

Chlamydial infection may result in pelvic inflammatory disease, infertility, and ectopic pregnancy. Chlamydia screening is recommended in sexually active women younger than 25 years of age and other women at increased risk and can be performed on vaginal swabs or urine samples.
Trainees dissatisfied with “tick box” ARCP, researchers find
Authors: Abi Rimmer
Journal: BMJ (2017)

Trainees are dissatisfied with the “tick box” nature of the annual review of competence progression (ARCP), researchers have found.

Researchers from UCL Medical School surveyed 96 trainees and 41 trainers about their perceptions of the validity of the ARCP. They found that there was “general dissatisfaction with ARCPs, especially among UK graduates,” and although trainers tended to view the process more positively they did voice negative views.1

The paper, published in …
Allogeneic and Autologous Transplantation In Patients with Aggressive B- and T-Cell Lymphomas
Authors: Frank Schueler, Madelaine Hoffmann, Christian Pfrepper, Said Daneschnejad, Thoralf Lange, Wolfram Pönisch, Haifa K. Al-Ali, Dietger W Niederwieser, Nadezda Basara
Journal: Blood (2010)
Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application.
Authors: Mariateresa Fulciniti, Teru Hideshima, Puru Nanjappa, Scott Rodig, Samir B Amin, Dheeraj Pelluru, Jagannath Pal, Rao Prabhala, Masood A Shammas, Pierfrancesco Tassone, Scott Mohrland, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2009)
Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Multiple Myeloma (MM): Long Term Follow-up in a Single Centre Series
Authors: Malek Benakli, Redhouane Ahmednacer, Amina Talbi, Farih Mehdid, Rachida Belhadj, Nadia Rahmoune, Farida Harieche, Fatiha Zerhouni, Rose-Marie Hamladji
Journal: Blood (2008)
Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma
Authors: Karl S Peggs, Irfan Kayani, Kirsty Thomson, Emma Morris, Panagiotis Kottaridis, Kirit M Ardeshna, Adele Fielding, Rachael Hough, Anthony H Goldstone, Ronjon Chakraverty, David C Linch, Stephen Mackinnon
Journal: Blood (2011)
P13.16 Changes in perfusion MR imaging in brain metastases after stereotactic radiotherapy
Authors: M. Kerkhof, I. Ganeff, R. G. J. Wiggenraad, G. J. Lycklama à Nijeholt, S. Hammer, M. J. B. Taphoorn, L. Dirven, M. J. Vos
Journal: Neuro-Oncology (2016)
Efficacy and safety of everolimus (eve) and exemestane (exe) in postmenopausal hormone-receptor positive (hr+) advanced breast cancer (abc) patients (pts) beyond clinical trials: preliminary results of the observational multicenter eva study
Authors: V. Torri, M.E. Cazzaniga, F. Galli, M.R. Valerio, C. Ficorella, O. Garrone, R. Palumbo, A. Fumagalli, G. Moretti, M. De Laurentiis, A. Frassoldati, S. Artale, A. Zambelli, P. Vici, M. Maur, D. Sartori, A. Fabi
Journal: Annals of Oncology (2016)